ITGAX and acute myeloid leukemia: 80% of AML with SRSF2 and ASXL1 mutations expressed two or more monocytic lineage markers (CD11c, CD14, or CD64), compared to 47% of AML cases with either ASXL1 or SRSF2 mutations, or with neither mutation [98].